Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
VaccinesGene Therapeutics & RNAi

PUBLISHER: Visiongain | PRODUCT CODE: 2050391

Cover Image

PUBLISHER: Visiongain | PRODUCT CODE: 2050391

Global mRNA Vaccines Market Report 2026-2036

PUBLISHED:
PAGES: 241 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 8164.52
PDF (Team License - Up to 6 Users)
USD 9666.03
PDF (Site License)
USD 11355.25
PDF (Enterprise License - Includes Free Datasets)
USD 14348.90

Add to Cart

Description

Table of Contents

List of Tables

The global mRNA vaccines market is projected to grow from US$9.7bn in 2026 to US$16.8bn by 2031 and US$34.7bn by 2036, at a CAGR of 13.6% over the forecast period.

Annual growth rates are forecast at 7.9% in 2026, 14.5% in 2031, and 16.2% in 2036, reflecting accelerating investment in mRNA platform development, expanding therapeutic applications beyond infectious disease, and growing adoption across oncology and autoimmune indications.

This growth is underpinned by continued advances in mRNA delivery system engineering, increasing adoption of self-amplifying mRNA technologies, and growing reliance on mRNA platforms for rapid vaccine development across pandemic preparedness and targeted therapeutic programmes.

Access a Free Sample of This Report

Download a sample to explore:

  • Market forecasts and segment breakdowns
  • Competitive and company-level insights
  • Key trends shaping the market
  • Trade, policy, and supply chain analysis

Technological Innovation Driving Market Expansion

Advances in lipid nanoparticle engineering and mRNA delivery systems are reshaping competition across the global mRNA vaccines market. Refinements to ionisable lipid structures, including optimisation of lipid head groups, hydrophobic tails, and lipid-to-mRNA ratios, are improving cytosolic delivery, endosomal escape, and transfection efficiency while reducing unintended inflammatory responses.

Development efforts are also broadening beyond conventional lipid nanoparticles toward organic and polymer-based carriers designed to improve biodegradability and reduce lipid-associated toxicity without compromising encapsulation performance. Formulation engineering focused on particle size distribution, surface characteristics, and excipient selection is improving mRNA stability and resilience across manufacturing and cold-chain distribution.

At the same time, the integration of AI-enabled drug discovery platforms and self-amplifying mRNA technologies is shortening vaccine and therapeutic development timelines, helping organisations broaden their pipeline of addressable indications.

Trade, Policy & Supply Chain Dynamics

  • The mRNA vaccines market is increasingly influenced by global trade dynamics, regulatory frameworks, and geopolitical developments.
  • The market depends heavily on specialised globally sourced raw materials including nucleotides, capping reagents, enzymes, lipids, single-use systems, analytical equipment, and cold-chain components, creating exposure to tariffs, export controls, and supply-chain constraints around GMP-grade materials.
  • US trade tariffs on imported biomanufacturing inputs and equipment are increasing procurement costs, extending lead times, and placing pressure on CDMOs and vaccine developers with cross-border supply networks.
  • In regulated sectors such as vaccines and biologics, compliance with data protection frameworks, manufacturing standards, and approval processes continues to shape market access, pricing, and operational execution across key regions.

Commercial Impact

  • Cost and pricing pressure: Rising input, manufacturing, and compliance costs are affecting CDMO margins and increasing overall programme budgets for mRNA vaccine developers
  • Supply chain shifts: Companies are accelerating US-based manufacturing investment, dual sourcing, and regional fill-finish capacity to reduce tariff exposure and improve supply-chain resilience
  • Regulatory influence: Market access and development timelines are shaped by evolving approval frameworks, pandemic preparedness mandates, and public procurement requirements across key regions
  • Competitive positioning: Companies with vertically integrated manufacturing capabilities and established regulatory credentials are better positioned to capture long-term mRNA vaccine market growth

Company Intelligence

The mRNA vaccines market features a mix of established biopharmaceutical leaders, specialist mRNA platform developers, and emerging therapeutics companies competing across scientific innovation, manufacturing scale, and regulatory capability.

Leading companies including BioNTech SE, Moderna, Pfizer, and Sanofi are strengthening their positions through platform development, strategic partnerships, and expansion into oncology, autoimmune, and personalised medicine indications.

Competition is increasingly defined by:

  • mRNA platform technology capability and delivery system innovation
  • Regulatory and manufacturing scale credentials
  • Pipeline breadth across infectious disease, oncology, and autoimmune applications
  • Ability to support rapid development and global distribution at scale

Newer entrants and specialist developers are also gaining traction where self-amplifying mRNA technologies, AI-enabled design, or targeted therapeutic focus create differentiation.

This report analyses how competitive positioning is evolving, identifying where value is being created and how strategies are expected to shift over the forecast period.

Key Questions Answered

  • What is the projected mRNA vaccines market size by 2036?
  • Which segments and regions will drive growth?
  • How will advances in delivery systems and self-amplifying mRNA technologies shape market evolution?
  • How will trade, policy, and supply chain dynamics impact manufacturing costs and market access?
  • Who are the leading companies and how will their positions evolve?

Report Scope and Data Coverage

  • Global mRNA vaccines market analysis
  • Revenue forecasts to 2036
  • Segment-level modelling across vaccine type, application, and end user
  • Regional and national market forecasts
  • Competitive intelligence on 11 leading companies

Includes both quantitative forecasting and qualitative strategic analysis, covering technology, competition, policy, and supply chain dynamics.

Segmentation Framework

By Type

  • Self-amplifying mRNA-based Vaccines
  • Conventional Non-amplifying mRNA-based Vaccines

By Application

  • Cancer
  • Infectious Disease
  • Autoimmune Diseases
  • Others

By End User

  • Hospitals and Clinics
  • Research Organisations
  • Others

Geographic Coverage

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA

Company Intelligence Coverage

This report includes detailed profiles of 11 leading companies active in the global mRNA vaccines market, including:

  • AIM Vaccine
  • Arcturus Therapeutics, Inc.
  • BioNTech SE
  • DAIICHI SANKYO COMPANY, LIMITED
  • etherna
  • Ethris
  • GSK plc
  • Moderna, Inc.
  • Pfizer Inc.
  • Sanofi
  • Strand Therapeutics

Each profile includes:

  • Business overview
  • Financial and market positioning
  • Product and technology capabilities
  • Strategic outlook

Bespoke Intelligence & Customisation

Visiongain also provides tailored intelligence and advisory services aligned to specific client requirements.

This includes:

  • Custom market segmentation and forecasts
  • Competitive benchmarking and strategy analysis
  • Policy and regulatory impact assessment
  • Supply chain and sourcing intelligence
  • Scenario modelling including tariffs and geopolitical risk

Why This Market Intelligence Matters

  • The mRNA vaccines market is evolving rapidly, driven by platform technology advances, expanding therapeutic applications, and shifting manufacturing and supply chain strategies.
  • Organisations that understand these dynamics will be better placed to capture growth opportunities, manage risk, and strengthen competitive positioning.
  • Purchase the mRNA Vaccines Market Report 2026-2036 to access the complete dataset, forecasts, and competitive analysis.
Show more
Product Code: PHA1387

Table of Contents

1 Report Overview

  • 1.1 Objectives of the Study
  • 1.2 Introduction to mRNA Vaccines Market
  • 1.3 What This Report Delivers
  • 1.4 Why You Should Read This Report
  • 1.5 Key Questions Answered by This Analytical Report Include:
  • 1.6 Who is This Report For?
  • 1.7 Methodology
    • 1.7.1 Market Definitions
    • 1.7.2 Market Evaluation & Forecasting Methodology
    • 1.7.3 Data Validation
      • 1.7.3.1 Primary Research
      • 1.7.3.2 Secondary Research
  • 1.8 Frequently Asked Questions (FAQs)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2 Executive Summary

3 Market Overview

  • 3.1 Key Findings
  • 3.2 Market Dynamics
  • 3.3 Impact Analysis
    • 3.3.1 Market Driving Factors
      • 3.3.1.1 Growing R&D Investments for Developing mRNA-based Vaccines
      • 3.3.1.2 Technological Advancements in Delivery Systems
      • 3.3.1.3 Increasing Government Initiatives and Policies to Promote Vaccination
    • 3.3.2 Market Restraining Factors
      • 3.3.2.1 High Price Association with mRNA Vaccine
      • 3.3.2.2 Stringent Regulations for Approval of mRNA Vaccine
    • 3.3.3 Market Opportunities
      • 3.3.3.1 Expanding Applications of mRNA Vaccine
      • 3.3.3.2 Growth of Localised mRNA Manufacturing & Tech Transfer Hubs
      • 3.3.3.3 Advancements in Self-amplifying mRNA (saRNA) Platforms
  • 3.4 U.S. Tariffs: What's the Impact on Global mRNA Vaccines Market?
    • 3.4.1 Overview
    • 3.4.2 V-Shaped Recovery Scenario
    • 3.4.3 Why V-Shaped Recovery?
      • 3.4.3.1 Impact from Tariffs
      • 3.4.3.2 Market Dynamics and Demand Recovery
      • 3.4.3.3 Policy and Funding Support
      • 3.4.3.4 Timeframe for Recovery
    • 3.4.4 U-Shaped Recovery Scenario
      • 3.4.4.1 Why U-Shaped Recovery?
      • 3.4.4.2 Impact from Tariffs
      • 3.4.4.3 Market Dynamics and Demand Recovery
      • 3.4.4.4 Policy and Funding Support
      • 3.4.4.5 Timeframe for Recovery
    • 3.4.5 L Shaped Recovery Scenario
      • 3.4.5.1 Why L-Shaped Recovery?
      • 3.4.5.2 Impact from Tariffs
      • 3.4.5.3 Market Dynamics and Demand Recovery
      • 3.4.5.4 Policy and Funding Support
      • 3.4.5.5 Timeframe for Recovery
    • 3.4.6 What Strategic Considerations Should Clients Factor into Their Near-term (2026-2031) and Long-term (2026-2036) Planning?
    • 3.4.7 Impact of U.S. and China Trade War on mRNA Vaccines Market
    • 3.4.8 How Might the Most Impacted Countries Experience Positive and Negative Effects Resulting from These Policy Changes?
  • 3.5 Porter's Five Forces Analysis
    • 3.5.1 Bargaining Power of Suppliers - Moderate to High
    • 3.5.2 Bargaining Power of Buyers - Moderate
    • 3.5.3 Competitive Rivalry - High
    • 3.5.4 Threat of Substitutes - Moderate
    • 3.5.5 Threat of New Entrants - Low
  • 3.6 PEST Analysis

4 mRNA Vaccines Market Analysis by Type

  • 4.1 Key Findings
  • 4.2 Type Segment: Market Attractiveness Index
  • 4.3 mRNA Vaccines Market Size Estimation and Forecast by Type
  • 4.4 Self-amplifying mRNA-based Vaccines
    • 4.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.4.2 Market Share by Region, 2026 & 2036 (%)
  • 4.5 Conventional Non-amplifying mRNA-based Vaccines
    • 4.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 4.5.2 Market Share by Region, 2026 & 2036 (%)

5 mRNA Vaccines Market Analysis by Application

  • 5.1 Key Findings
  • 5.2 Application Segment: Market Attractiveness Index
  • 5.3 mRNA Vaccines Market Size Estimation and Forecast by Application
  • 5.4 Cancer
    • 5.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.4.2 Market Share by Region, 2026 & 2036 (%)
  • 5.5 Infectious Disease
    • 5.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.5.2 Market Share by Region, 2026 & 2036 (%)
  • 5.6 Autoimmune Diseases
    • 5.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.6.2 Market Share by Region, 2026 & 2036 (%)
  • 5.7 Others
    • 5.7.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 5.7.2 Market Share by Region, 2026 & 2036 (%)

6 mRNA Vaccines Market Analysis by End-users

  • 6.1 Key Findings
  • 6.2 End-users Segment: Market Attractiveness Index
  • 6.3 mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 6.4 Hospitals and Clinics
    • 6.4.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.4.2 Market Share by Region, 2026 & 2036 (%)
  • 6.5 Research Organisations
    • 6.5.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.5.2 Market Share by Region, 2026 & 2036 (%)
  • 6.6 Others
    • 6.6.1 Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
    • 6.6.2 Market Share by Region, 2026 & 2036 (%)

7 mRNA Vaccines Market Analysis by Region

  • 7.1 Key Findings
  • 7.2 Regional Market Size Estimation and Forecast

8 North America mRNA Vaccines Market Analysis

  • 8.1 Key Findings
  • 8.2 North America mRNA Vaccines Market Attractiveness Index
  • 8.3 North America mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 8.4 North America mRNA Vaccines Market Size Estimation and Forecast by Country
  • 8.5 North America mRNA Vaccines Market Size Estimation and Forecast by Type
  • 8.6 North America mRNA Vaccines Market Size Estimation and Forecast by Application
  • 8.7 North America mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 8.8 U.S. mRNA Vaccines Market Analysis
  • 8.9 Canada mRNA Vaccines Market Analysis

9 Europe mRNA Vaccines Market Analysis

  • 9.1 Key Findings
  • 9.2 Europe mRNA Vaccines Market Attractiveness Index
  • 9.3 Europe mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 9.4 Europe mRNA Vaccines Market Size Estimation and Forecast by Country
  • 9.5 Europe mRNA Vaccines Market Size Estimation and Forecast by Type
  • 9.6 Europe mRNA Vaccines Market Size Estimation and Forecast by Application
  • 9.7 Europe mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 9.8 Germany mRNA Vaccines Market Analysis
  • 9.9 UK mRNA Vaccines Market Analysis
  • 9.10 France mRNA Vaccines Market Analysis
  • 9.11 Italy mRNA Vaccines Market Analysis
  • 9.12 Spain mRNA Vaccines Market Analysis
  • 9.13 Rest of Europe mRNA Vaccines Market Analysis

10 Asia Pacific mRNA Vaccines Market Analysis

  • 10.1 Key Findings
  • 10.2 Asia Pacific mRNA Vaccines Market Attractiveness Index
  • 10.3 Asia Pacific mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 10.4 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Country
  • 10.5 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Type
  • 10.6 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by Application
  • 10.7 Asia Pacific mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 10.8 Japan mRNA Vaccines Market Analysis
  • 10.9 China mRNA Vaccines Market Analysis
  • 10.10 India mRNA Vaccines Market Analysis
  • 10.11 Australia mRNA Vaccines Market Analysis
  • 10.12 Rest of Asia Pacific mRNA Vaccines Market Analysis

11 Latin America mRNA Vaccines Market Analysis

  • 11.1 Key Findings
  • 11.2 Latin America mRNA Vaccines Market Attractiveness Index
  • 11.3 Latin America mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 11.4 Latin America mRNA Vaccines Market Size Estimation and Forecast by Country
  • 11.5 Latin America mRNA Vaccines Market Size Estimation and Forecast by Type
  • 11.6 Latin America mRNA Vaccines Market Size Estimation and Forecast by Application
  • 11.7 Latin America mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 11.8 Brazil mRNA Vaccines Market Analysis
  • 11.9 Mexico mRNA Vaccines Market Analysis
  • 11.10 Rest of Latin America mRNA Vaccines Market Analysis

12 MEA mRNA Vaccines Market Analysis

  • 12.1 Key Findings
  • 12.2 MEA mRNA Vaccines Market Attractiveness Index
  • 12.3 MEA mRNA Vaccines Market by Country, 2026, 2031 & 2036 (US$ Million)
  • 12.4 MEA mRNA Vaccines Market Size Estimation and Forecast by Country
  • 12.5 MEA mRNA Vaccines Market Size Estimation and Forecast by Type
  • 12.6 MEA mRNA Vaccines Market Size Estimation and Forecast by Application
  • 12.7 MEA mRNA Vaccines Market Size Estimation and Forecast by End-users
  • 12.8 GCC mRNA Vaccines Market Analysis
  • 12.9 South Africa mRNA Vaccines Market Analysis
  • 12.10 Rest of MEA mRNA Vaccines Market Analysis

13 Company Profiles

  • 13.1 Pfizer Inc.
    • 13.1.1 Company Snapshot
    • 13.1.2 Company Overview
    • 13.1.3 Financial Analysis
      • 13.1.3.1 Net Revenue, 2021-2025
      • 13.1.3.2 R&D, 2021-2025
      • 13.1.3.3 Regional Market Shares, 2025
      • 13.1.3.4 Business Segment Market Shares, 2025
    • 13.1.4 Product Benchmarking
    • 13.1.5 Strategic Outlook
  • 13.2 Moderna, Inc.
    • 13.2.1 Company Snapshot
    • 13.2.2 Company Overview
    • 13.2.3 Financial Analysis
      • 13.2.3.1 Net Revenue, 2021-2025
      • 13.2.3.2 R&D, 2021-2025
      • 13.2.3.3 Regional Market Shares, 2025
      • 13.2.3.4 Business Segment Market Shares, 2025
    • 13.2.4 Product Benchmarking
    • 13.2.5 Strategic Outlook
  • 13.3 BioNTech SE
    • 13.3.1 Company Snapshot
    • 13.3.2 Company Overview
    • 13.3.3 Financial Analysis
      • 13.3.3.1 Net Revenue, 2021-2025
      • 13.3.3.2 R&D, 2021-2025
      • 13.3.3.3 Regional Market Shares, 2025
      • 13.3.3.4 Business Segment Market Shares, 2025
    • 13.3.4 Product Benchmarking
    • 13.3.5 Strategic Outlook
  • 13.4 GSK plc
    • 13.4.1 Company Snapshot
    • 13.4.2 Company Overview
    • 13.4.3 Financial Analysis
      • 13.4.3.1 Net Revenue, 2021-2025
      • 13.4.3.2 R&D, 2021-2025
      • 13.4.3.3 Regional Market Shares, 2025
      • 13.4.3.4 Business Segment Market Shares, 2025
    • 13.4.4 Product Benchmarking
    • 13.4.5 Strategic Outlook
  • 13.5 DAIICHI SANKYO COMPANY, LIMITED
    • 13.5.1 Company Snapshot
    • 13.5.2 Company Overview
    • 13.5.3 Financial Analysis
      • 13.5.3.1 Net Revenue, 2021-2025
      • 13.5.3.2 R&D, 2021-2025
      • 13.5.3.3 Regional Market Shares, 2025
    • 13.5.4 Product Benchmarking
  • 13.6 Ethris
    • 13.6.1 Company Snapshot
    • 13.6.2 Company Overview
    • 13.6.3 Product Benchmarking
    • 13.6.4 Strategic Outlook
  • 13.7 AIM Vaccine
    • 13.7.1 Company Snapshot
    • 13.7.2 Company Overview
    • 13.7.3 Financial Analysis
      • 13.7.3.1 Net Revenue, 2022-2024
    • 13.7.4 Product Benchmarking
    • 13.7.5 Strategic Outlook
  • 13.8 Arcturus Therapeutics, Inc.
    • 13.8.1 Company Snapshot
    • 13.8.2 Company Overview
    • 13.8.3 Product Benchmarking
    • 13.8.4 Strategic Outlook
  • 13.9 Sanofi
    • 13.9.1 Company Snapshot
    • 13.9.2 Company Overview
    • 13.9.3 Financial Analysis
      • 13.9.3.1 Net Revenue, 2021-2025
      • 13.9.3.2 R&D, 2021-2025
      • 13.9.3.3 Regional Market Shares, 2025
      • 13.9.3.4 Business Segment Market Shares, 2025
    • 13.9.4 Product Benchmarking
    • 13.9.5 Strategic Outlook

14 Conclusion and Recommendations

  • 14.1 Concluding Remarks from Visiongain
  • 14.2 Recommendations for Market Players
Show more
Product Code: PHA1387

List of Tables

  • Table 1 mRNA Vaccines Market Snapshot, 2026 & 2036 (US$ million, CAGR %)
  • Table 2 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
  • Table 3 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
  • Table 4 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
  • Table 5 mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 6 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 7 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 8 mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 9 Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 10 Infectious Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 11 Autoimmune DiseasesSegment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 12 Other Applications Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 13 mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 14 Hospitals and Clinics Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 15 Research Organisations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 16 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 17 mRNA Vaccines Market Forecast by Region, 2026-2036 (US$ Million, AGR%, CAGR%)
  • Table 18 North America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 19 North America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 20 North America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 21 North America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 22 U.S. mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 23 Canada mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 24 Europe mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 25 Europe mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 26 Europe mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 27 Europe mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 28 Germany mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 29 UK mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 30 France mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 31 Italy mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 32 Spain mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 33 Rest of Europe mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 34 Asia Pacific mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 35 Asia Pacific mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 36 Asia Pacific mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 37 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 38 Japan mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 39 China mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 40 India mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 41 Australia mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 42 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 43 Latin America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 44 Latin America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 45 Latin America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 46 Latin America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 47 Brazil mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 48 Mexico mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 49 Rest of Latin America mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 50 MEA mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Billion, AGR%, CAGR%)
  • Table 51 MEA mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 52 MEA mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 53 MEA mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %, CAGR %)
  • Table 54 GCC mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 55 South Africa mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 56 Rest of MEA mRNA Vaccines Market Forecast, 2026-2036 (US$ Mn, AGR%, CAGR%)
  • Table 57 Pfizer Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 58 Pfizer Inc.: Product Benchmarking
  • Table 59 Pfizer Inc.: Strategic Outlook
  • Table 60 Moderna, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 61 Moderna, Inc.: Product Benchmarking
  • Table 62 Moderna, Inc.: Strategic Outlook
  • Table 63 BioNTech SE: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 64 BioNTech SE: Product Benchmarking
  • Table 65 BioNTech SE: Strategic Outlook
  • Table 66 GSK plc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 67 GSK plc: Product Benchmarking
  • Table 68 GSK plc: Strategic Outlook
  • Table 69 DAIICHI SANKYO COMPANY, LIMITED: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 70 DAIICHI SANKYO COMPANY, LIMITED: Product Benchmarking
  • Table 71 Ethris: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 72 Ethris: Product Benchmarking
  • Table 73 Ethris: Strategic Outlook
  • Table 74 AIM Vaccine: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 75 AIM Vaccine: Product Benchmarking
  • Table 76 AIM Vaccine: Strategic Outlook
  • Table 77 Arcturus Therapeutics, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 78 Arcturus Therapeutics, Inc.: Product Benchmarking
  • Table 79 Arcturus Therapeutics, Inc.: Strategic Outlook
  • Table 80 Sanofi: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
  • Table 81 Sanofi: Product Benchmarking
  • Table 82 Sanofi: Strategic Outlook

List of Figures

  • Figure 1 mRNA Vaccines Market Segmentation
  • Figure 2 mRNA Vaccines Market by Type: Market Attractiveness Index
  • Figure 3 mRNA Vaccines Market by Application: Market Attractiveness Index
  • Figure 4 mRNA Vaccines Market by End-users: Market Attractiveness Index
  • Figure 5 mRNA Vaccines Market Attractiveness Index by Region
  • Figure 6 mRNA Vaccines Market: Market Dynamics
  • Figure 7 mRNA Vaccines Market: Impact Analysis
  • Figure 8 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: V-Shaped Recovery Scenario
  • Figure 9 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: U-Shaped Recovery Scenario
  • Figure 10 mRNA Vaccines Market by Region, 2026-2036 (US$ Million, AGR %), Tariff Impact: L-Shaped Recovery Scenario
  • Figure 11 Short Term & Long Term Planning
  • Figure 12 Impact of U.S. and China Trade War
  • Figure 13 Most Impacted Countries
  • Figure 14 mRNA Vaccines Market: Porter's Five Forces Analysis
  • Figure 15 mRNA Vaccines Market: PEST Analysis
  • Figure 16 mRNA Vaccines Market Attractiveness Index by Type
  • Figure 17 mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 18 mRNA Vaccines Market Share Forecast by Type, 2026, 2031, 2036 (%)
  • Figure 19 Self-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 20 Self-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 21 Conventional Non-amplifying mRNA-based Vaccines Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 22 Conventional Non-amplifying mRNA-based Vaccines Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 23 mRNA Vaccines Market Attractiveness Index by Type
  • Figure 24 mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
  • Figure 25 mRNA Vaccines Market Share Forecast by Application, 2026, 2031, 2036 (%)
  • Figure 26 Cancer Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 27 Cancer Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 28 Infectious Disease Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 29 Infectious Disease Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 30 Autoimmune Diseases Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 31 Autoimmune Diseases Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 32 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 33 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 34 mRNA Vaccines Market Attractiveness Index by End-users
  • Figure 35 mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 36 mRNA Vaccines Market Share Forecast by End-users, 2026, 2031, 2036 (%)
  • Figure 37 Hospitals and Clinics Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 38 Hospitals and Clinics Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 39 Research Organisations Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 40 Research Organisations Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 41 Others Segment Market Forecast by Region, 2026-2036 (US$ Million, AGR %)
  • Figure 42 Others Segment Market Share Forecast by Region, 2026 & 2036 (%)
  • Figure 43 mRNA Vaccines Market Forecast by Region 2026, 2031, 2036 (Revenue, CAGR%)
  • Figure 44 mRNA Vaccines Market Share Forecast by Region 2026, 2031, 2036 (%)
  • Figure 45 mRNA Vaccines Market by Region, 2026-2036 (US$ Mn)
  • Figure 46 North America mRNA Vaccines Market Attractiveness Index
  • Figure 47 North America mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 48 North America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 49 North America mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 50 North America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 51 North America mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 52 North America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
  • Figure 53 North America mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
  • Figure 54 North America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 55 North America mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 56 U.S. mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 57 Canada mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 58 Europe mRNA Vaccines Market Attractiveness Index
  • Figure 59 Europe mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 60 Europe mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 61 Europe mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 62 Europe mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 63 Europe mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 64 Europe mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
  • Figure 65 Europe mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
  • Figure 66 Europe mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 67 Europe mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 68 Germany mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 69 UK mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 70 France mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 71 Italy mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 72 Spain mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 73 Rest of Europe mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 74 Asia Pacific mRNA Vaccines Market Attractiveness Index
  • Figure 75 Asia Pacific mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 76 Asia Pacific mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 77 Asia Pacific mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 78 Asia Pacific mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 79 Asia Pacific mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 80 Asia Pacific mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
  • Figure 81 Asia Pacific mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
  • Figure 82 Asia Pacific mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 83 Asia Pacific mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 84 Japan mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 85 China mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 86 India mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 87 Australia mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 88 Rest of Asia Pacific mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 89 Latin America mRNA Vaccines Market Attractiveness Index
  • Figure 90 Latin America mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 91 Latin America mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 92 Latin America mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 93 Latin America mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 94 Latin America mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 95 Latin America mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
  • Figure 96 Latin America mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
  • Figure 97 Latin America mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 98 Latin America mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 99 Brazil mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 100 Mexico mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 101 Rest of Latin America mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 102 MEA mRNA Vaccines Market Attractiveness Index
  • Figure 103 MEA mRNA Vaccines Market by Region, 2026, 2031 & 2036 (US$ Million)
  • Figure 104 MEA mRNA Vaccines Market Forecast by Country, 2026-2036 (US$ Million, AGR %)
  • Figure 105 MEA mRNA Vaccines Market Share Forecast by Country, 2026 & 2036 (%)
  • Figure 106 MEA mRNA Vaccines Market Forecast by Type, 2026-2036 (US$ Million, AGR %)
  • Figure 107 MEA mRNA Vaccines Market Share Forecast by Type, 2026 & 2036 (%)
  • Figure 108 MEA mRNA Vaccines Market Forecast by Application, 2026-2036 (US$ Million, AGR %)
  • Figure 109 MEA mRNA Vaccines Market Share Forecast by Application, 2026 & 2036 (%)
  • Figure 110 MEA mRNA Vaccines Market Forecast by End-users, 2026-2036 (US$ Million, AGR %)
  • Figure 111 MEA mRNA Vaccines Market Share Forecast by End-users, 2026 & 2036 (%)
  • Figure 112 GCC mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 113 South Africa mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 114 Rest of MEA mRNA Vaccines Market Forecast, 2026-2036 (US$ Million, AGR %)
  • Figure 115 Pfizer Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
  • Figure 116 Pfizer Inc.: R&D, 2021-2025 (US$ Million, AGR %)
  • Figure 117 Pfizer Inc.: Regional Market Shares (%), 2025
  • Figure 118 Pfizer Inc.: Business Segment Market Shares (%), 2025
  • Figure 119 Moderna, Inc.: Net Revenue, 2021-2025 (US$ Million, AGR %)
  • Figure 120 Moderna, Inc.: R&D, 2021-2025 (US$ Million, AGR %)
  • Figure 121 Moderna, Inc.: Regional Market Shares (%), 2025
  • Figure 122 Moderna, Inc.: Business Segment Market Shares (%), 2025
  • Figure 123 BioNTech SE: Net Revenue, 2021-2025 (US$ Million, AGR %)
  • Figure 124 BioNTech SE: R&D, 2021-2025 (US$ Million, AGR %)
  • Figure 125 BioNTech SE: Regional Market Shares (%), 2025
  • Figure 126 BioNTech SE: Business Segment Market Shares (%), 2025
  • Figure 127 GSK plc: Net Revenue, 2021-2025 (US$ Million, AGR %)
  • Figure 128 GSK plc: R&D, 2021-2025 (US$ Million, AGR %)
  • Figure 129 GSK plc: Regional Market Shares (%), 2025
  • Figure 130 GSK plc: Business Segment Market Shares (%), 2025
  • Figure 131 DAIICHI SANKYO COMPANY, LIMITED: Net Revenue, 2021-2025 (US$ Million, AGR %)
  • Figure 132 DAIICHI SANKYO COMPANY, LIMITED: R&D, 2021-2025 (US$ Million, AGR %)
  • Figure 133 DAIICHI SANKYO COMPANY, LIMITED: Regional Market Shares (%), 2025
  • Figure 134 AIM Vaccine: Net Revenue, 2022-2024 (US$ Million, AGR %)
  • Figure 135 Sanofi: Net Revenue, 2021-2025 (US$ Million, AGR %)
  • Figure 136 Sanofi: R&D, 2021-2025 (US$ Million, AGR %)
  • Figure 137 Sanofi: Regional Market Shares (%), 2025
  • Figure 138 Sanofi: Business Segment Market Shares (%), 2025
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!